Clinical Trial Update: A Study of Efficacy and Safety of Sepranolone (UC1010) in Patients With Premenstrual Dysphoric Disorder (PMDD) [Phase 2]

View source ↗

Summary

Phase 2 trial update of Sepranolone (UC1010) for efficacy and safety in Premenstrual Dysphoric Disorder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Premenstrual Dysphoric Disorder

Drugs mentioned

• Sepranolone (UC1010)

Snippet

Sponsor: Asarina Pharma | Conditions: Premenstrual Dysphoric Disorder | Phase 2 | Status: COMPLETED